---
title: "PLYX.US (PLYX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PLYX.US/news.md"
symbol: "PLYX.US"
name: "PLYX.US"
parent: "https://longbridge.com/en/quote/PLYX.US.md"
datetime: "2026-05-20T19:35:59.480Z"
locales:
  - [en](https://longbridge.com/en/quote/PLYX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PLYX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PLYX.US/news.md)
---

# PLYX.US (PLYX.US) — Related News

### [Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News](https://longbridge.com/en/news/286423563.md)
*2026-05-14T05:15:34.000Z*
> Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News

### [Most and least shorted healthcare stocks with up to $2B market cap in May](https://longbridge.com/en/news/285083732.md)
*2026-05-04T14:02:20.000Z*
> Short sellers have increased their positions in small-cap healthcare stocks, particularly those under $2 billion market 

### [Polaryx Therapeutics | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/283985661.md)
*2026-04-24T10:56:10.000Z*
### [Polaryx Therapeutics, Inc. (PLYX) Receives a Buy from Maxim Group](https://longbridge.com/en/news/283719703.md)
*2026-04-22T20:25:20.000Z*
> Polaryx Therapeutics, Inc. (PLYX) received a Buy rating from Maxim Group, as reported by analyst Jason McCarthy. The com

### [Polaryx Shares Rise As FDA Grants Fast-track Status Across All SOTERIA Trial Indications](https://longbridge.com/en/news/283560702.md)
*2026-04-21T21:15:25.000Z*
> Polaryx Therapeutics, Inc. (PLYX) shares rose 10% after the FDA granted Fast Track Designation for all four indications 

### [Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News](https://longbridge.com/en/news/282852650.md)
*2026-04-15T05:15:41.000Z*
> Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News

### [Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher   - Time to Buy?](https://longbridge.com/en/news/282762994.md)
*2026-04-15T01:14:10.000Z*
> Polaryx Therapeutics (NASDAQ:PLYX) shares rose 4.9% to $6.47, despite a significant drop in trading volume. Maxim Group